Aptazyme-directed A-to-I RNA editing.

Area of Science:

• Biotechnology
• Molecular Biology
• Gene Therapy

Background:

• RNA editing, particularly using human Adenosine Deaminases Acting on RNA (ADAR) enzymes, presents a promising therapeutic strategy.
• ADAR-mediated RNA editing is reversible, tunable, specific, and less immunogenic than DNA editing methods like CRISPR.
• A key limitation is the lack of precise temporal and spatial control over RNA editing events.

Purpose of the Study:

• To develop a novel RNA editing strategy with precise temporal and spatial control.
• To engineer a system for small molecule-inducible RNA editing using aptazymes and the BoxB-λN-ADAR system.
• To demonstrate conditional activation and deactivation of A-to-I RNA editing in target mRNA.

Main Methods:

• Incorporation of aptazymes into the guide RNA of the BoxB-λN-ADAR system to create a small molecule-inducible RNA editing tool.
• Utilizing aptazymes that trigger self-cleavage upon addition or removal of small molecules to control guide RNA availability.
• Developing protocols for constructing guide RNA plasmids and conducting small molecule-induced RNA editing experiments in cellular models.

Main Results:

• Successful implementation of a small molecule-inducible RNA editing strategy.
• Demonstration of conditional activation and deactivation of A-to-I RNA editing on target mRNA using switch aptazymes.
• Established protocols for the creation of regulatory guide RNAs and experimental execution in cells.

Conclusions:

• The developed aptazyme-based system enables precise temporal and spatial control of ADAR-mediated RNA editing.
• This approach offers a safer and more controllable alternative to permanent gene editing techniques.
• The findings pave the way for advanced RNA-based therapeutics with tunable editing capabilities.